A Bay Area company that allows protein analysis at the single cell level has raised $1.86 million in funding.
Zephyrus Biosciences plans to develop and commercialize its single cell Western blotting system, called the scWestern system, that allows researchers to study proteins in thousands of single cells, the company said in a release. In June, it published its process in Nature Methods.
The technology comes out of the University of California, Berkeley, based on research from bioinstrumentation professor Amy Herr.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The funding includes $1.5 million in seed funding from Life Sciences Angels, Mission Bay Capital, the Angel Forum and the Stanford-StartX Fund, as well as a number of individual investors. In addition, Zephyrus has received a Phase 1 SBIR grant from the NIH and $10,000 from the U.C. Bakar Fellows Program at Berkeley.
The company’s associated with accelerators QB3, BayBio, Berkeley Skydeck and StartX.
“Our vision is to provide the tools to enable researchers to unlock the cell-to-cell variation that drives cancer pathogenesis and stem cell differentiation,” CEO and co-founder Kelly Gardner said in a statement. “We believe that this technology will fundamentally transform how researchers think about cancer and other diseases.”
Indeed, the company cited the following as potential applications of the scWestern technologies:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
- Identification of cellular subpopulations
- Further analysis of enriched cell populations after FACS sorting
- Cell signaling studies
- Cancer heterogeneity studies for targeted therapeutic development
- Studies of models for drug resistance
This is how it works:
